Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Has Average Price Target of $35.85 According to Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been assigned an average recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $35.85.

Several research firms recently weighed in on DNLI. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Thursday, October 15th. Wedbush reiterated an “outperform” rating and set a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. Robert W. Baird set a $34.00 target price on Denali Therapeutics in a report on Friday, August 7th. UBS Group upped their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, B. Riley Financial increased their price objective on Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th.

Insiders Place Their Bets

In related news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the sale, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 9.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in shares of Denali Therapeutics by 237.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 48,300 shares of the company’s stock valued at $998,000 after acquiring an additional 34,000 shares during the period. Manchester Capital Management LLC increased its holdings in Denali Therapeutics by 5,505.6% in the 3rd quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock worth $42,000 after acquiring an additional 1,982 shares in the last quarter. E. Ohman J or Asset Management AB raised its stake in Denali Therapeutics by 3.1% during the 3rd quarter. E. Ohman J or Asset Management AB now owns 165,000 shares of the company’s stock worth $3,411,000 after acquiring an additional 5,000 shares during the period. Reyes Financial Architecture Inc. bought a new stake in Denali Therapeutics during the 3rd quarter worth approximately $125,000. Finally, B. Riley Wealth Advisors Inc. raised its stake in Denali Therapeutics by 38.2% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 17,713 shares of the company’s stock worth $366,000 after acquiring an additional 4,900 shares during the period. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $19.29 on Thursday. The stock’s 50 day simple moving average is $20.89 and its two-hundred day simple moving average is $21.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -6.79 and a beta of 1.02. Denali Therapeutics has a fifty-two week low of $13.75 and a fifty-two week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same period last year, the business posted ($0.72) EPS. As a group, analysts expect that Denali Therapeutics will post -2.70 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.